Hep C Studies on Faldaprevir Will Be Heard at EASL
Boehringer Ingelheim’s STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress
Published on April 10, 2013
Boehringer Ingelheim today announced that data from its pivotal STARTVerso™ 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress™ 2013: 48th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place from April 24-28 in Amsterdam, The Netherlands.
The STARTVerso™ 1 trial evaluated faldaprevir (BI 201335), an investigational oral protease inhibitor specifically designed to target and inhibit viral replication in the liver, in combination with pegylated interferon and ribavirin (PegIFN/RBV). The study was conducted in treatment-naïve patients with genotype-1 infection, the most common and one of the most challenging types of hepatitis C to cure.
Continue reading this entire article:http://www.news-medical.net/news/20130410/Boehringer-Ingelheims-STARTVerso-1-Phase-3-hepatitis-C-data-to-be-presented-at-EASL-Congress.aspx
New Drug Application Submitted for Gilead’s Sofosbuvir
Hep C Research Chimps May Be Switched Out for Mice